⌕
Cullinan Therapeutics · CGEM · Nasdaq
Tenet 55 · Mixed
Compare
$9.28−2.37%At closeTenet 55 · Mixed
$9.28−0.23 (−2.37%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Cullinan Therapeutics (CGEM) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is CGEM's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 16:33 ET
Cullinan Therapeutics, Inc. (CGEM) Presents at UBS Global Biopharma Conference 2026 Transcript

Cullinan Therapeutics, Inc. ( CGEM ) UBS Global Biopharma Conference 2026 November 17, 2026 9:00 AM EST Company Participants Nadim Ahmed - President, CEO & Director Jeffrey Jones - Chief Medical Officer Conference Call P…

CGEM −2.4% todayRead at source ↗
● GlobeNewsWireNov 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren's disease will be shared in December Velinotamig (BCMA TCE) data presented at ACR Convergence 2026; global Phase 1/2 study in autoimmune cytopenias initi…

CGEM −2.4% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 10:00 ETCOMPANY'S OWN WORDS
Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T c…

CGEM −2.4% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 09:14 ETCOMPANY'S OWN WORDS
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers…

CGEM −2.4% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 10:55 ET
Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?

The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 129.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in r…

CGEM −2.4% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA

Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA…

CGEM −2.4% todayRead at source ↗
● Business WireOct 19, 2026 · 07:00 ET
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monot…

CGEM −2.4% todayRead at source ↗
● GlobeNewsWireOct 8, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T c…

CGEM −2.4% todayRead at source ↗
● Seeking AlphaSep 29, 2026 · 07:30 ET
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases

I think Cullinan Therapeutics' recent pullback is a compelling price entry ahead of their clinical updates. CGEM has scheduled updates for its autoimmune pipeline for December 2026. The combined CLN-978 results could hel…

CGEM −2.4% todayRead at source ↗
● MarketBeatSep 28, 2026 · 07:02 ET
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

Cullinan Therapeutics NASDAQ: CGEM outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentation…

CGEM −2.4% todayRead at source ↗
● GlobeNewsWireSep 24, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November  CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren's disease in December CLN-049 (FLT3 TCE) updated data from the …

CGEM −2.4% todayRead at source ↗
● GlobeNewsWireSep 21, 2026 · 12:00 ET
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T …

CGEM −2.4% todayRead at source ↗
● Defense WorldSep 15, 2026 · 04:29 ET
Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM

Engineers Gate Manager LP raised its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ: CGEM) by 130.9% in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Co…

CGEM −2.4% todayRead at source ↗
● Seeking AlphaSep 14, 2026 · 12:31 ET
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript

Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript…

CGEM −2.4% todayRead at source ↗
● GlobeNewsWireSep 14, 2026 · 07:00 ET
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engager…

CGEM −2.4% todayRead at source ↗
● GuruFocusSep 13, 2026 · 20:00 ET
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial e…

CGEM −2.4% todayRead at source ↗
● GlobeNewsWireSep 10, 2026 · 13:00 ET
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, Septe…

CGEM −2.4% todayRead at source ↗
● Seeking AlphaAug 26, 2026 · 05:41 ET
Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset

Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value drivers, reducing reliance on external funding. Zipalertinib's positive Phase 3 results and upcoming regulatory milestone…

CGEM −2.4% todayRead at source ↗
● Defense WorldAug 26, 2026 · 04:01 ET
Bank of America Corp DE Acquires 170,417 Shares of Cullinan Therapeutics, Inc. $CGEM

Bank of America Corp DE lifted its stake in Cullinan Therapeutics, Inc. (NASDAQ: CGEM) by 49.2% in a recent quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutiona…

CGEM −2.4% todayRead at source ↗
● Business WireAug 19, 2026 · 12:03 ET
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC PRINCET…

CGEM −2.4% todayRead at source ↗

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just CGEM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.